Allarity Therapeutics announced that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib (2X‑121) is on schedule, with completion expected in the third quarter of 2026. The contract development and manufacturing organization (CDMO) in Europe is operating under Good Manufacturing Practice (GMP) standards required by the U.S. Food and Drug Administration and the European Medicines Agency, ensuring that clinical‑grade drug product will be available when the company initiates a pivotal Phase 3 trial.
The manufacturing milestone removes a key execution risk for Allarity. A ready supply of stenoparib is essential for the company’s Fast‑Track‑designated program, which was granted by the FDA on August 26 2025. The dual‑mechanism of action—PARP and WNT pathway inhibition—targets advanced ovarian cancer, and the company’s proprietary Drug Response Predictor (DRP®) companion diagnostic is expected to improve patient selection and trial efficiency.
Allarity’s financial position underscores the importance of this milestone. The company reported a net loss of $11.2 million for 2025, a significant improvement from a $25.1 million loss in 2024, and generated $320 thousand in license revenue that year. Cash on hand as of December 31 2025 was $14.7 million. A $20 million non‑convertible debt financing closed in March 2026 extends the cash runway into mid‑2028, highlighting the company’s reliance on external financing to fund development.
CEO Thomas Jensen said the progress “reflects our confidence in the long‑term potential of the program and is particularly important as we work to leverage the FDA Fast Track designation to accelerate the development and potential approval of stenoparib.” The company continues to run two Phase 2 trials in ovarian cancer and a Phase 2 study of stenoparib plus temozolomide in relapsed small‑cell lung cancer, all of which will benefit from the secured manufacturing capacity.
The DRP® companion diagnostic has received a Notice of Allowance from the U.S. Patent and Trademark Office, with formal grant expected within three months, securing exclusivity until at least 2039. Together, the manufacturing progress, regulatory advantage, and diagnostic support position Allarity to advance stenoparib toward pivotal trials and, ultimately, market approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.